SEC filings and other documents

Varseta-M delivers unprecedented efficacy in late-line CRC, with broad expansion and strong funding.

Varseta-M shows strong efficacy in late-line CRC, with pivotal trials and new partnerships advancing.

Varseta-M shows transformative efficacy in late-line CRC, with pivotal study prep and strong financials.

Masked ADC shows 28% response in late-line CRC; registrational study planned by 2027.

Vaseta M and CX801 advance in clinical trials, targeting major unmet needs in oncology.

Varseta-M delivers high response rates and improved safety in late-line CRC, advancing to pivotal trials.

CX-2051 delivered promising results in colorectal cancer, driving expansion and future pipeline growth.

Masked anti-EpCAM ADC shows 28% response in late-stage CRC; major update set for Q1 2026.

CX-2051 demonstrated strong efficacy in late-line CRC, with plans for FDA engagement in 2026.

CX-2051 delivers promising late-line CRC results; cash runway extends into 2027.

Masked ADC shows promising efficacy and safety in late-line CRC; pivotal data due Q1 2026.

Strong early results for masked ADC in CRC and progress in masked Interferon for melanoma.

CX-2051 shows promising efficacy in late-line CRC, with pivotal data and expansion plans ahead.

CX-2051 shows robust efficacy in late-line CRC, with financials supporting pipeline expansion.

CX-2051 shows strong efficacy and safety in late-line CRC, with pivotal data due Q1 2026.

CX-2051 showed promising efficacy and safety in late-line CRC, backed by $100M financing.